Drug Trial Radar · NCT06094283
First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males
Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Dec 20, 2023
Primary completion
Jun 18, 2024
Study completion Jun 18, 2024
Sponsor
- Lead sponsor
- YourChoice Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 25 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single ascending oral dose(s) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YCT-529 in healthy male subjects.
Conditions
- Male Contraception
Interventions
YCT-529Drug
Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
YCT-529 PlaceboDrug
YCT-529 Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and nature of any adverse events, dose-limiting adverse events and serious adverse adverse events.Time frame: Baseline to 43 days for subjects participating in Cohorts 1 and 2 participating in the 2 periods; Baseline to 10 weeks for Cohorts 1 and 2 that also complete the fed portion of the study; and Baseline to 16 weeks if waiting for other cohorts to finish
- Vital signs assessment (heart rate)Time frame: Baseline to Day 15
- Vital signs assessment (blood pressure)Time frame: Baseline to Day 15
- Vital signs assessment (oral temperature)Time frame: Baseline to Day 15
- 12-lead ECG assessment (heart rate)Time frame: Baseline to Day 15
- 12-lead ECG assessment (QT interval)Time frame: Baseline to Day 15
- 12-lead ECG assessment (QTcF Interval)Time frame: Baseline to Day 15
- 12-lead ECG assessment (PR Interval)Time frame: Baseline to Day 15
- 12-lead ECG assessment (QRS Duration)Time frame: Baseline to Day 15
- Clinical laboratory assessments (hematology blood sample tests)Time frame: Baseline to Day 15
- Clinical laboratory assessments (coagulation blood sample tests)Time frame: Baseline to Day 15
- Clinical laboratory assessments (clinical chemistry blood sample tests)Time frame: Baseline to Day 15
- Clinical laboratory assessments (urine sample tests)Time frame: Baseline to Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Nottingham, East Midlands, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.